57 results
P
cancer patients
I/C
immune checkpoint inhibitors (ICIs), antibiotic (ATB) use
O
poor survival outcomes, including overall survival (OS) and progression-free survival (PFS)
P
I/C
plant-based drugs
O
cytotoxic plants
P
six laboratories
I/C
round-robin testing, in-house DNA extraction and qPCR protocols
O
concentration of extracted DNA
P
preschoolers
I/C
iron-fortified milk (IFM), no intervention
O
hemoglobin, serum ferritin
P
adult clients
I/C
Therapeutic Assessment
O
treatment process, clients' symptoms, clients' self-enhancement
P
health professionals
I/C
occupational exposure to antineoplastic drugs (ANDs), no occupational exposure to ANDs
O
primary DNA damage
P
youth with psychiatric disorders, healthy peers
I/C
transdiagnostic meta-analysis of structural neuroimaging experiments, youth psychiatric disorders vs. healthy peers
O
reduced grey matter volume (GMV) of amygdala and lateral orbitofrontal cortex, enhanced GMV of ventromedial prefrontal cortex and precuneus, functional connectivity and decoding analyses
P
bacteria, yeast, fungi
I/C
carbon catabolite repression (CCR), different carbon sources
O
regulation of gene expression, plant-microbe interactions
P
Lung squamous cell carcinoma (LUSC), TCGA dataset, GEO datasets, clinical samples
I/C
FOXD1 expression, high FOXD1 expression, low FOXD1 expression
O
favorable prognosis, immune score, proportions of immune cell infiltration subgroups
P
patients with established coronary artery disease (CAD)
I/C
colchicine, placebo or usual care
O
cardiovascular (CV) death, myocardial infarction (MI), or stroke